Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy
| Autor: | Djordje Atanackovic, Tim Luetkens, Destiny Omili, Thierry Iraguha, Forat Lutfi, Nancy M. Hardy, Xiaoxuan Fan, Stephanie V. Avila, Kapil K. Saharia, Jennifer S. Husson, Silke V. Niederhaus, Philip Margiotta, Seung T. Lee, Jennie Y. Law, Heather D. Mannuel, Erica Vander Mause, Sherri Bauman, Patricia Lesho, Kim Hankey, John Baddley, Mehmet Kocoglu, Jean A. Yared, Aaron P. Rapoport, Saurabh Dahiya |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Blood. 140:152-156 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|